Report cover image

Global Pharmaceutical Tracker, 2022

Publisher Frost & Sullivan
Published Jul 13, 2022
Length 22 Pages
SKU # MC17300457

Description

Global Pharmaceutical Tracker, 2022

This research service offers comprehensive discussions about the key approvals, mergers and acquisitions, product licensing deals, and digital partnerships of the pharmaceutical industry in 2022. A renewed focus on operational excellence and digital transformation will push top-line pharmaceutical industry growth and drive strong partnerships with small and mid-size pharma and digital solution vendors. The digital implosion is transforming the pharma business model to achieve digital maturity. Big pharma is moving toward technology vendor partnerships to accelerate digitization and de-risk investments in in-house capabilities, platforms, and solutions. Diminishing R&D pipelines, stagnant productivity during the last 2 decades, and the disruption in clinical trials due to the pandemic have led to a surge in partnerships. Small and mid-sized companies will continue to attract big pharma and private equity (PE) firms. New modalities and technologies will remain attractive for licensing deals, giving biotech licensor candidates a higher chance of negotiating contract terms and up-front payments.

Table of Contents

22 Pages
    • Key Highlights
    • Pharmaceutical Industry-Companies to Watch
    • New Modality Approvals
    • Key Mergers & Acquisitions
    • Key In-licensing & Out-licensing Deals
    • Digital Partnerships
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.